← All trials
NCT05586776
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2028
- First posted
- Oct 19, 2022
- Last posted
- Dec 23, 2022
- Enrollment
- 2700
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, IrvineLead sponsor
- University of California, DavisCollaborator
- University of California, DavisStudy director
- University of California, IrvineOverall official - principal investigator
- University of California, IrvineReponsible party - principal investigator
- University of California, San FranciscoCollaborator
- University of California, San FranciscoStudy director
- University of MassachusettsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.